Minute Insight: Abbott Touts 14-Day FreeStyle Libre 3 Data

Shortly after the FDA approved Abbott's FreeStyle Libre 3 continuous glucose monitor system, the company announced new clinical data showing that it is the most accurate 14-day CGM system available.

Minute Insight
• Source: Informa/Alamy

Clinical data presented at the American Diabetes Association (ADA) conference in New Orleans support's Abbott’s claim that its FreeStyle Libre 3 system is the first and only 14-day continuous glucose monitoring (CGM) system to achieve a sub-8% overall mean absolute relative difference (MARD).

Clinical data from a 100-patient, 14-day non-randomized study, presented by Abbott at the ADA meeting, showed FreeStyle Libre 3...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Minute Insights

More from Medtech Insight

EU Pilot Features ‘All-In-One’ Regulatory Path For Drug/Diagnostic Trials

 
• By 

The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.

European Medtechs Reiterate Opposition To Reciprocal Tariffs On US Imports

 
• By 

EU countermeasures against US tariffs suggest medtech categories exported to the EU could be targeted for tariffs. MedTech Europe and the German IVDs industry have stressed the negative effects this would have on patient care.

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.